Bucci Cristina, Zingone Fabiana, Tammaro Stella, Iovino Paola, Santonicola Antonella, Ciacci Carolina
Department of Medicine and Surgery, Scuola Medica Salernitana, AOU San Giovanni di Dio and Ruggi d'Aragona, IBD Center at the University of Salerno, Salerno, Italy.
Gastroenterol Res Pract. 2017;2017:6719345. doi: 10.1155/2017/6719345. Epub 2017 Aug 7.
Inflammatory bowel diseases (IBD) are chronic gastrointestinal disorders influencing many aspects of the patient's life and accounting for substantial social costs. They require long-term therapies and regular contact with the clinic of reference. Our aim is to investigate therapy adherence and identify predictors of adherence.
151 patients were recruited in IBD clinic at the University of Salerno filled in the modified Morisky Medication Adherence Scale, a standardized questionnaire provided during the visit.
Overall, 71.5% of the patients report to take all medications regularly. According to the scale, our population showed a 62.5% medium-high adherence to oral 5-ASA, a 72% medium-high adherence to immunomodulators, a 60% medium-high adherence to oral steroids, and 94.9% adherence to biologics. Younger patients tend to be less compliant to the therapy. The main reasons for the low adherence to therapy were the "hassle of sticking to the medication plan" and "their feeling better." . In Italy, where the healthcare system covers most of the expenses for IBD therapy, almost 30% of IBD patients report low compliance to therapy. Healthcare givers should improve the knowledge regarding the disease and favor the development of combined drugs that would simplify the daily medication plan.
炎症性肠病（IBD）是慢性胃肠道疾病，会影响患者生活的诸多方面，并产生高昂的社会成本。这些疾病需要长期治疗，并定期与参考诊所联系。我们的目的是调查治疗依从性并确定依从性的预测因素。
在萨勒诺大学的IBD诊所招募了151名患者，他们填写了改良的Morisky药物依从性量表，这是在就诊期间提供的标准化问卷。
总体而言，71.5%的患者报告定期服用所有药物。根据该量表，我们的患者群体对口服5-ASA的中度高依从性为62.5%，对免疫调节剂的中度高依从性为72%，对口服类固醇的中度高依从性为60%，对生物制剂的依从性为94.9%。年轻患者往往对治疗的依从性较低。治疗依从性低的主要原因是“坚持用药计划麻烦”和“感觉好多了”。在意大利，医疗保健系统承担了IBD治疗的大部分费用，近30%的IBD患者报告治疗依从性低。医疗保健提供者应提高对该疾病的认识，并支持开发能简化每日用药计划的联合药物。
